Trial Condition(s):
Endometriosis
Drug-drug interaction study between orally administered rifampicin and vilaprisan
Bayer Identifier:
17773
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
This study will be conducted in a single center, open-label study with a single group fixed sequence design to evaluate the effect of repeated oral administration of 600 mg RIF(Rifampicin) given once daily over 11 days on the single oral dose pharmacokinetics of VPR(Vilaprisan) and on MDZ(Midazolam) as a reference (probe) substance.
Inclusion Criteria
- Healthy female postmenopausal subjects - Age: 45 to 65 years (inclusive) - Body mass index (BMI) : ≥20 and ≤32 kg/m² - Race: White
Exclusion Criteria
- Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance - Relevant diseases within the last 4 weeks prior to the first drug administration - Existing chronic diseases requiring medication - Known or suspected malignant tumors (including history of malignant tumors, with a status after treatment), known or suspected benign tumors of the liver and pituitary (including after treatment) - Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal - Regular use of medicines - Repeated use of drugs during 1 week before first study drug administration which might affect absorption (e.g. laxatives, loperamide, metoclopramide, antacids, H2-receptor antagonists)
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Berlin, Germany, 13353 | Contact Us: E-mail: [email protected] Phone: +49 30 300139003 |
Trial Design
Non-randomized, non-blinded, non-placebo-controlled study to investigate the influence of repeated daily administration of 600 mg rifampicin given once daily over 11 days on the pharmacokinetics, safety, and tolerability of a single oral dose of 4 mg vilaprisan in healthy postmenopausal women.
Trial Type:
Interventional
Intervention Type:
Drug
Trial Purpose:
Basic Science
Allocation:
N/A
Blinding:
Open Label
Assignment:
Single Group Assignment
Trial Arms:
1
Primary Outcome
- AUC of Vilaprisan in plasma with co-medication RifampicinTimeframe: blood sampling for pharmacokinetics of Vilaprisan (LC-MS/MS) at the following time points post administration of Vilaprisan and Midazolam: 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,8,12,15 hour, thereafter daily sampling up to 14 days
- Cmax of Vilaprisan in plasma with co-medication RifampicinTimeframe: blood sampling for pharmacokinetics of Vilaprisan (LC-MS/MS) at the following time points post administration of Vilaprisan and Midazolam: 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,8,12,15 hour, thereafter daily sampling up to 14 days
- AUC of Vilaprisan in plasma without co-medication RifampicinTimeframe: blood sampling for pharmacokinetics of Vilaprisan (LC-MS/MS) at the following time points post administration of Vilaprisan and Midazolam: 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,8,12,15 hour, thereafter daily sampling up to 14 days
- Cmax of Vilaprisan in plasma without co-medication RifampicinTimeframe: blood sampling for pharmacokinetics of Vilaprisan (LC-MS/MS) at the following time points post administration of Vilaprisan and Midazolam: 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,8,12,15 hour, thereafter daily sampling up to 14 days
Additional Information
Copyright © Bayer
Powered by
